Rallybio Corporation (NASDAQ:RLYB) Receives Consensus Rating of “Reduce” from Analysts

Shares of Rallybio Corporation (NASDAQ:RLYB) have been assigned an average rating of “Reduce” from the five brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $40.00.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC increased its holdings in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after acquiring an additional 373,821 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares in the last quarter. Susquehanna International Group LLP grew its position in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the period. XTX Topco Ltd grew its position in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares in the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Trading Up 1.0%

Rallybio stock opened at $10.91 on Monday. Rallybio has a 12 month low of $1.76 and a 12 month high of $11.49. The stock’s 50 day simple moving average is $5.86 and its two-hundred day simple moving average is $5.28. The firm has a market cap of $57.60 million, a PE ratio of -4.26 and a beta of -1.13.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.